Dube Eric M 4
4 · Travere Therapeutics, Inc. · Filed Apr 15, 2026
Research Summary
AI-generated summary of this filing
Travere (TVTX) CEO Eric Dube Sells 64,000 Shares
What Happened
- Eric M. Dube, CEO of Travere Therapeutics (TVTX), had 64,000 performance restricted stock units vest on April 13, 2026 (acquired at $0) and sold all 64,000 shares in open-market/private sales on April 15, 2026 for aggregate proceeds of $2,629,975. Sales broken down: 56,815 shares at a weighted average $41.01 ($2,329,983), 7,165 shares at a weighted average $41.75 ($299,139), and 20 shares at $42.66 ($853).
Key Details
- Filing date: April 15, 2026; Period of report: April 13, 2026.
- Award/Acquisition: 64,000 PSUs vested on April 13, 2026 (acquired at $0) following FDA approval of FILSPARI per footnote.
- Sales: Open-market/private sales on April 15, 2026 totaling 64,000 shares for $2,629,975.
- Plan/Tax: Sales were made under a written 10b5-1 plan adopted June 16, 2025 and include shares sold to cover tax withholding on vesting.
- Price ranges: tranche one weighted avg $41.01 (range $40.51–$41.51); tranche two weighted avg $41.75 (range $41.52–$42.42). Detailed per-price breakdown available on request.
- Shares owned after transaction: Not specified in the filing excerpt provided.
- Filing timeliness: No late filing flag noted in this report.
Context
- This sequence is a common post-vesting transaction: PSUs vested (an award/acquisition event), and the resulting shares were sold (partly to satisfy tax withholding) under a pre-established 10b5-1 plan. Such sales are typically routine and do not, by themselves, indicate managerial views about the company’s stock beyond the mechanics of vesting and tax obligations.
Insider Transaction Report
Form 4
Dube Eric M
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Award
Common Stock
[F1]2026-04-13+64,000→ 496,886 total - Sale
Common Stock
[F2][F3]2026-04-15$41.01/sh−56,815$2,329,983→ 440,071 total - Sale
Common Stock
[F2][F4]2026-04-15$41.75/sh−7,165$299,139→ 432,906 total - Sale
Common Stock
[F2]2026-04-15$42.66/sh−20$853→ 432,886 total
Footnotes (4)
- [F1]On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.
- [F2]This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
- [F3]The weighted average sale price for the transaction reported was $41.01, and the range of prices were between $40.51 and $41.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The weighted average sale price for the transaction reported was $41.75, and the range of prices were between $41.52 and $42.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact|2026-04-15